Duchenne muscular dystrophy drug flunks Phase 3 confirmatory trial

NS Pharma’s Duchenne muscular dystrophy drug Viltepso failed its confirmatory study. Despite the failure, the company is keeping faith in the drug and running further …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Missing Teeth and Joint Pain? RA May Be Imminent

Although the mechanistic relationship is still unclear, that periodontal disease is connected with rheumatoid arthritis (RA) is no longer in question. A new study suggests

May 3, 2024

Mainz Biomed Provides Year-End Corporate Review 2023 – Biotech Investments

Issuer: Mainz BioMed N.V. / Key word(s): Miscellaneous 09.01.2024 / 14:01 CET/CEST The issuer is solely responsible for the content of this announcement. Mainz Biomed

January 10, 2024

High-fiber diets may help control the adverse effects of antibiotic treatments on beneficial gut microbiota

The role of diet in controlling the structure and function of the gut via chemical environment modulation.

August 30, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.